Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $56,491 | $9,165 | $7,189 | $40,750 |
| Short-Term Investments | $41,053 | $4,087 | $15,862 | $0 |
| Receivables | $0 | $0 | $40 | $110 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $908 | $959 | $1,281 | $1,610 |
| Total Curr. Assets | $98,451 | $14,211 | $24,371 | $42,470 |
| Property Plant & Equip (Net) | $149 | $296 | $565 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | -$0 | $0 |
| Total NC Assets | $149 | $296 | $565 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $98,600 | $14,507 | $24,936 | $42,470 |
| Liabilities | – | – | – | – |
| Payables | $943 | $647 | $1,151 | $1,090 |
| Short-Term Debt | $111 | $532 | $146 | $249 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $2,680 | $2,260 | $2,398 | $2,716 |
| Total Curr. Liab. | $3,734 | $3,439 | $3,695 | $4,054 |
| LT Debt | $0 | $90 | $205 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | -$0 | $0 |
| Total NC Liab. | $0 | $90 | $205 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $111 | $240 | $351 | $0 |
| Total Liabilities | $3,734 | $3,529 | $3,901 | $4,054 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $69 | $6 | $4 | $25 |
| Retained Earnings | -$94,421 | -$66,901 | -$47,872 | -$29,818 |
| AOCI | -$37 | $1 | $105 | -$0 |
| Other Equity | $189,255 | $77,872 | $68,798 | $68,208 |
| Total Equity | $94,866 | $10,978 | $21,035 | $38,416 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $98,600 | $14,507 | $24,936 | $42,470 |
| Net Debt | -$56,380 | -$8,543 | -$6,837 | -$40,501 |